Sen. Richard Blumenthal Sells Off Shares of Oncology Institute, Inc. (NASDAQ:STLN)

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $1,001 and $15,000 in Oncology Institute stock on September 23rd.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Trading Up 4.8%

NASDAQ:STLN opened at $6.59 on Wednesday. Oncology Institute, Inc. has a 12 month low of $2.32 and a 12 month high of $7.13. The company has a 50-day moving average price of $6.47.

Oncology Institute (NASDAQ:STLN) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter. The firm had revenue of $161.28 million for the quarter, compared to the consensus estimate of $152.80 million. Research analysts predict that Oncology Institute, Inc. will post -0.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

STLN has been the topic of a number of research analyst reports. BTIG Research increased their price target on Oncology Institute from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Weiss Ratings assumed coverage on Oncology Institute in a report on Thursday, August 6th. They set a “sell (d-)” rating for the company. Needham & Company LLC lifted their price objective on Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Finally, Lake Street Capital assumed coverage on Oncology Institute in a research note on Monday, July 6th. They issued a “buy” rating and a $10.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Institutional Trading of Oncology Institute

Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp bought a new position in Oncology Institute during the 2nd quarter worth approximately $8,432,000. The Manufacturers Life Insurance Company acquired a new position in Oncology Institute during the second quarter valued at approximately $111,000. WINTON GROUP Ltd acquired a new position in Oncology Institute during the second quarter valued at approximately $102,000. Engineers Gate Manager LP bought a new stake in Oncology Institute in the second quarter valued at approximately $67,000. Finally, Squarepoint Ops LLC bought a new stake in Oncology Institute in the second quarter valued at approximately $396,000. 36.86% of the stock is owned by institutional investors.

Insider Activity at Oncology Institute

In other news, Director Brad Hively sold 298,853 shares of Oncology Institute stock in a transaction on Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the transaction, the director directly owned 411,976 shares of the company’s stock, valued at $2,681,963.76. This trade represents a 42.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 12,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $6.54 per share, with a total value of $78,480.00. Following the acquisition, the insider directly owned 10,660,858 shares in the company, valued at $69,722,011.32. This trade represents a 0.11% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 4.40% of the stock is currently owned by corporate insiders.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.